Published in Exp Neurol on August 22, 2007
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur J Neurosci (2009) 1.42
Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. J Neural Transm (Vienna) (2011) 1.12
The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol (2010) 1.11
Endocannabinoid signalling and the deteriorating brain. Nat Rev Neurosci (2015) 1.03
Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2. Neurochem Int (2008) 0.88
Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats. Drug Des Devel Ther (2012) 0.85
Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats. Int J Nanomedicine (2012) 0.84
The therapeutic potential of cannabinoids for movement disorders. Mov Disord (2015) 0.83
The cannabinoid system in Parkinson's disease: multiple targets to motor effects. Exp Neurol (2008) 0.83
Intrastriatal injections of KN-93 ameliorates levodopa-induced dyskinesia in a rat model of Parkinson's disease. Neuropsychiatr Dis Treat (2013) 0.82
Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism. Brain Struct Funct (2014) 0.81
In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability. Prostaglandins Other Lipid Mediat (2009) 0.81
Brain morphometry and the neurobiology of levodopa-induced dyskinesias: current knowledge and future potential for translational pre-clinical neuroimaging studies. Front Neurol (2014) 0.81
Microglial phenotypes in Parkinson's disease and animal models of the disease. Prog Neurobiol (2016) 0.80
The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats. Neurosci Res (2011) 0.80
Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats. Neurobiol Dis (2014) 0.80
Capsaicin-sensitive primary sensory neurons in the mouse express N-Acyl phosphatidylethanolamine phospholipase D. Neuroscience (2009) 0.79
Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection. Mol Neurodegener (2015) 0.79
New insights on endocannabinoid transmission in psychomotor disorders. Prog Neuropsychopharmacol Biol Psychiatry (2012) 0.79
Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors. Eur J Neurosci (2012) 0.79
TRPV1 on astrocytes rescues nigral dopamine neurons in Parkinson's disease via CNTF. Brain (2015) 0.78
Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia. Br J Pharmacol (2015) 0.78
Nigrostriatal denervation changes the effect of cannabinoids on subthalamic neuronal activity in rats. Psychopharmacology (Berl) (2010) 0.78
Endocannabinoid modulation of dopaminergic motor circuits. Front Pharmacol (2012) 0.77
Effect of Tianqi antitremor granules on behavioral manifestations and expression of G protein-coupled receptor kinase 6 and β-arrestin1 in levodopa-induced dyskinesia in a rat model of Parkinson's disease. Drug Des Devel Ther (2013) 0.77
Anatomy of Graft-induced Dyskinesias: Circuit Remodeling in the Parkinsonian Striatum. Basal Ganglia (2012) 0.76
Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target. Front Neurosci (2017) 0.75
The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesioned rats. Drug Des Devel Ther (2014) 0.75
Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy. Parkinsons Dis (2016) 0.75
Multi-Functional Diarylurea Small Molecule Inhibitors of TRPV1 with Therapeutic Potential for Neuroinflammation. AAPS J (2016) 0.75
New transient receptor potential vanilloid subfamily member 1 positron emission tomography radioligands: synthesis, radiolabeling, and preclinical evaluation. ACS Chem Neurosci (2013) 0.75
Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity. Front Pharmacol (2016) 0.75
Repetitive transcranial magnetic stimulation (rTMS) improves behavioral and biochemical deficits in levodopa-induced dyskinetic rats model. Oncotarget (2016) 0.75
Cannabinoid Modulation of Memory Consolidation in Rats: Beyond the Role of Cannabinoid Receptor Subtype 1. Front Pharmacol (2017) 0.75
Capsaicin prevents degeneration of dopamine neurons by inhibiting glial activation and oxidative stress in the MPTP model of Parkinson's disease. Exp Mol Med (2017) 0.75
Palmitoyl Serotonin Inhibits L-dopa-induced Abnormal Involuntary Movements in the Mouse Parkinson Model. Exp Neurobiol (2016) 0.75
Capsaicin Protects Against Oxidative Insults and Alleviates Behavioral Deficits in Rats with 6-OHDA-Induced Parkinson's Disease via Activation of TRPV1. Neurochem Res (2017) 0.75
The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature (1997) 30.59
Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med (2002) 7.72
Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A (2002) 5.33
Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature (2007) 4.36
Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci (1999) 3.45
The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci (2000) 3.41
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci (2003) 3.25
Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther (2004) 3.14
Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci U S A (2000) 2.87
Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain. Brain Res Mol Brain Res (2005) 2.18
The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J Biol Chem (2001) 2.13
Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol (2003) 2.09
Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience (2006) 2.07
Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci (2002) 2.01
Evidence for novel cannabinoid receptors. Pharmacol Ther (2005) 2.00
Animal models of neurological deficits: how relevant is the rat? Nat Rev Neurosci (2002) 1.96
Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol (2005) 1.96
Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol (2002) 1.90
Are cannabinoids endogenous ligands for the VR1 capsaicin receptor? Trends Pharmacol Sci (2000) 1.80
Anandamide - the other side of the coin. Trends Pharmacol Sci (2000) 1.78
Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology (2004) 1.73
Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain (2004) 1.65
A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis (2004) 1.65
Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease? Exp Neurol (2005) 1.64
Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors. J Neurosci (2003) 1.41
Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci (2002) 1.40
The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. Proc Natl Acad Sci U S A (2006) 1.39
A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J Neurosci (2006) 1.34
Oxidative metabolism of endocannabinoids. Prostaglandins Leukot Essent Fatty Acids (2002) 1.34
Unawareness of dyskinesias in Parkinson's and Huntington's diseases. Neurol Sci (2001) 1.32
Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J (2000) 1.32
Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. J Neurosci (2000) 1.31
New perspectives on enigmatic vanilloid receptors. Trends Neurosci (2000) 1.28
Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia. J Neurosci (2006) 1.28
Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. J Neurochem (2006) 1.26
The spectrum of levodopa-induced dyskinesias. Ann Neurol (2000) 1.17
Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J Neurochem (2006) 1.17
Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. Eur J Neurosci (2003) 1.16
Pharmacological characterization of the anandamide cyclooxygenase metabolite: prostaglandin E2 ethanolamide. J Pharmacol Exp Ther (2002) 1.13
Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1 receptor-mediated response. Cell Mol Life Sci (2003) 1.12
Transient receptor potential vanilloid subtype 1 mediates cell death of mesencephalic dopaminergic neurons in vivo and in vitro. J Neurosci (2005) 1.10
Quantification of endocannabinoids in rat biological samples by GC/MS: technical and theoretical considerations. Prostaglandins Other Lipid Mediat (2006) 1.08
Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon. Arch Neurol (1992) 1.07
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology (2001) 1.03
Effect of bilateral 6-OHDA lesions of the substantia nigra on locomotor activity in the rat. Brain Res (1994) 1.02
A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. FASEB J (2005) 1.02
Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications. Biol Psychiatry (2005) 1.00
Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiol Dis (2006) 0.99
Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neurol (1998) 0.98
Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. J Neurochem (2003) 0.97
Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat. Mol Pharmacol (2005) 0.95
A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats. Neuropharmacology (2006) 0.94
Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia. Exp Neurol (2004) 0.93
The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neurons. Life Sci (1995) 0.92
The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology (2004) 0.91
Motor complications in Parkinson's disease and the clinical significance of rotational behavior in the rat: have we wasted our time? Exp Neurol (2005) 0.87
The cannabinoid agonists WIN 55,212-2 and CP 55,940 attenuate rotational behavior induced by a dopamine D1 but not a D2 agonist in rats with unilateral lesions of the nigrostriatal pathway. Brain Res (1995) 0.80
Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med (2002) 7.72
Gender differences in drug responses. Pharmacol Res (2006) 2.50
Propofol enhances memory formation via an interaction with the endocannabinoid system. Anesthesiology (2011) 1.76
Endocannabinoids in the rat basolateral amygdala enhance memory consolidation and enable glucocorticoid modulation of memory. Proc Natl Acad Sci U S A (2009) 1.75
Cannabimimetic effects of osteopathic manipulative treatment. J Am Osteopath Assoc (2005) 1.63
Transport infrastructure surveillance and monitoring by electromagnetic sensing: the ISTIMES project. Sensors (Basel) (2010) 1.60
Comparative evaluation of simple indices of insulin resistance. Metabolism (2004) 1.42
WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur J Neurosci (2009) 1.42
Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology (2006) 1.28
Fat-induced satiety factor oleoylethanolamide enhances memory consolidation. Proc Natl Acad Sci U S A (2009) 1.25
The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs. Int Rev Neurobiol (2009) 1.20
Involvement of NOX2 in the development of behavioral and pathologic alterations in isolated rats. Biol Psychiatry (2009) 1.17
Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. Eur J Neurosci (2003) 1.16
Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats. Psychopharmacology (Berl) (2005) 1.15
Fish oil, insulin sensitivity, insulin secretion and glucose tolerance in healthy people: is there any effect of fish oil supplementation in relation to the type of background diet and habitual dietary intake of n-6 and n-3 fatty acids? Nutr Metab Cardiovasc Dis (2006) 1.14
N-Acylethanolamines in human reproductive fluids. Chem Phys Lipids (2002) 1.11
Anandamide hydrolysis: a new target for anti-anxiety drugs? Trends Mol Med (2003) 1.11
Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr Res (2007) 1.09
Quantification of endocannabinoids in rat biological samples by GC/MS: technical and theoretical considerations. Prostaglandins Other Lipid Mediat (2006) 1.08
Hindbrain noradrenergic input to the hypothalamic PVN mediates the activation of oxytocinergic neurons induced by the satiety factor oleoylethanolamide. Am J Physiol Endocrinol Metab (2013) 1.07
Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br J Psychiatry (2009) 1.06
Evidence that anandamide-signaling regulates human sperm functions required for fertilization. Mol Reprod Dev (2002) 1.06
Prenatal exposure to a cannabinoid agonist produces memory deficits linked to dysfunction in hippocampal long-term potentiation and glutamate release. Proc Natl Acad Sci U S A (2003) 1.05
Wired to run: exercise-induced endocannabinoid signaling in humans and cursorial mammals with implications for the 'runner's high'. J Exp Biol (2012) 1.05
Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study. Stroke (2002) 1.04
The fat-induced satiety factor oleoylethanolamide suppresses feeding through central release of oxytocin. J Neurosci (2010) 1.04
Developmental exposure to cannabinoids causes subtle and enduring neurofunctional alterations. Int Rev Neurobiol (2009) 1.04
The satiety signal oleoylethanolamide stimulates oxytocin neurosecretion from rat hypothalamic neurons. Peptides (2013) 1.02
Structural effects and neurofunctional sequelae of developmental exposure to psychotherapeutic drugs: experimental and clinical aspects. Pharmacol Rev (2004) 1.02
Endocannabinoids in amygdala and nucleus accumbens mediate social play reward in adolescent rats. J Neurosci (2012) 1.00
Regulation of brain anandamide by acute administration of ethanol. Biochem J (2007) 0.99
Neuroendocrine profile in a rat model of psychosocial stress: relation to oxidative stress. Antioxid Redox Signal (2013) 0.98
CB1 receptor selective activation inhibits beta-amyloid-induced iNOS protein expression in C6 cells and subsequently blunts tau protein hyperphosphorylation in co-cultured neurons. Neurosci Lett (2006) 0.98
Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. Int J Neuropsychopharmacol (2009) 0.97
Genetic factors involved in the effects of developmental low-level alcohol induced behavioral alterations in rats. Neuropsychopharmacology (2002) 0.96
Cannabis and the developing brain: insights from behavior. Eur J Pharmacol (2008) 0.95
The NADPH oxidase NOX2 controls glutamate release: a novel mechanism involved in psychosis-like ketamine responses. J Neurosci (2010) 0.95
CB1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum. J Neurochem (2007) 0.95
Prenatal exposure to the CB1 receptor agonist WIN 55,212-2 causes learning disruption associated with impaired cortical NMDA receptor function and emotional reactivity changes in rat offspring. Cereb Cortex (2005) 0.94
Exercise-induced endocannabinoid signaling is modulated by intensity. Eur J Appl Physiol (2012) 0.94
Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model. J Neurosci Res (2008) 0.93
Determination of anandamide and other fatty acyl ethanolamides in human serum by electrospray tandem mass spectrometry. Anal Biochem (2006) 0.93
Developmental consequences of perinatal cannabis exposure: behavioral and neuroendocrine effects in adult rodents. Psychopharmacology (Berl) (2010) 0.93
Androgens induce dopaminergic neurotoxicity via caspase-3-dependent activation of protein kinase Cdelta. Endocrinology (2009) 0.93
Genetic deletion of fatty acid amide hydrolase alters emotional behavior and serotonergic transmission in the dorsal raphe, prefrontal cortex, and hippocampus. Neuropsychopharmacology (2010) 0.92
Perinatal exposure to delta-9-tetrahydrocannabinol causes enduring cognitive deficits associated with alteration of cortical gene expression and neurotransmission in rats. Addict Biol (2007) 0.92
Neurokinin 1 receptor antagonism requires norepinephrine to increase serotonin function. Eur Neuropsychopharmacol (2006) 0.91
A role for endocannabinoids in viral-induced dyskinetic and convulsive phenomena. Exp Neurol (2005) 0.90
Biological mechanisms associated with increased perseveration and hyperactivity in a genetic mouse model of neurodevelopmental disorder. Psychoneuroendocrinology (2012) 0.90
Effects of perinatal exposure to delta-9-tetrahydrocannabinol on the emotional reactivity of the offspring: a longitudinal behavioral study in Wistar rats. Psychopharmacology (Berl) (2008) 0.88
Glutamatergic alterations and mitochondrial impairment in a murine model of Alzheimer disease. Neurobiol Aging (2011) 0.88
Acetaminophen differentially enhances social behavior and cortical cannabinoid levels in inbred mice. Prog Neuropsychopharmacol Biol Psychiatry (2012) 0.87
Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of sub-chronic PCP and MK-801. Behav Brain Res (2009) 0.87
Evaluation of the emotional phenotype and serotonergic neurotransmission of fatty acid amide hydrolase-deficient mice. Psychopharmacology (Berl) (2010) 0.87
Isolation rearing-induced reduction of brain 5α-reductase expression: relevance to dopaminergic impairments. Neuropharmacology (2011) 0.86
Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB₁ receptors: implications for schizophrenia. Neuropsychopharmacology (2013) 0.86
Novelty-induced emotional arousal modulates cannabinoid effects on recognition memory and adrenocortical activity. Neuropsychopharmacology (2013) 0.86
Principles and therapeutic relevance for targeting mitochondria in aging and neurodegenerative diseases. Curr Pharm Des (2011) 0.85
The endocannabinoid transport inhibitor AM404 differentially modulates recognition memory in rats depending on environmental aversiveness. Front Behav Neurosci (2012) 0.85
Altered serotonergic function may partially account for behavioral endophenotypes in steroid sulfatase-deficient mice. Neuropsychopharmacology (2011) 0.84
Novel codrugs with GABAergic activity for dopamine delivery in the brain. Int J Pharm (2012) 0.83
Prenatal exposure to the cannabinoid receptor agonist WIN 55,212-2 increases glutamate uptake through overexpression of GLT1 and EAAC1 glutamate transporter subtypes in rat frontal cerebral cortex. Neuropharmacology (2007) 0.83
Altering endocannabinoid neurotransmission at critical developmental ages: impact on rodent emotionality and cognitive performance. Front Behav Neurosci (2012) 0.83
Developmental exposure to methylmercury elicits early cell death in the cerebral cortex and long-term memory deficits in the rat. Int J Dev Neurosci (2008) 0.83
Prenatal exposure to carbon monoxide affects postnatal cellular electrophysiological maturation of the rat heart: a potential substrate for arrhythmogenesis in infancy. Circulation (2004) 0.82
Monoaminergic changes in locus coeruleus and dorsal raphe nucleus following noradrenaline depletion. Neurochem Res (2009) 0.82
The effects of nitric oxide on striatal serotoninergic transmission involve multiple targets: an in vivo microdialysis study in the awake rat. Brain Res (2004) 0.82
The endocannabinoid system during development: emphasis on perinatal events and delayed effects. Vitam Horm (2009) 0.82
Delta(9)-tetrahydrocannabinol increases endogenous extracellular glutamate levels in primary cultures of rat cerebral cortex neurons: involvement of CB(1) receptors. J Neurosci Res (2002) 0.82
Cognitive impairment and increased brain neurosteroids in adult rats perinatally exposed to low millimolar blood alcohol concentrations. Psychoneuroendocrinology (2007) 0.81
Androgens exacerbate motor asymmetry in male rats with unilateral 6-hydroxydopamine lesion. Horm Behav (2011) 0.81
Role of cannabinoidergic mechanisms in ethanol self-administration and ethanol seeking in rat adult offspring following perinatal exposure to Delta9-tetrahydrocannabinol. Toxicol Appl Pharmacol (2007) 0.81
Sleep deprivation increases oleoylethanolamide in human cerebrospinal fluid. J Neural Transm (Vienna) (2009) 0.81
Striatal 6-OHDA lesion in mice: Investigating early neurochemical changes underlying Parkinson's disease. Behav Brain Res (2009) 0.81
Olfactory memory is impaired in a triple transgenic model of Alzheimer disease. Behav Brain Res (2011) 0.81
A synthetic cannabinoid agonist promotes oligodendrogliogenesis during viral encephalitis in rats. Exp Neurol (2010) 0.80
The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats. Neurosci Res (2011) 0.80
Relationship between plasma insulin and left ventricular mass in normotensive participants of the Gubbio Study. Clin Endocrinol (Oxf) (2003) 0.80
Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery. Int J Pharm (2011) 0.80
Chronic nandrolone administration induces dysfunction of the reward pathway in rats. Steroids (2014) 0.79
Altered regulation of glutamate release and decreased functional activity and expression of GLT1 and GLAST glutamate transporters in the hippocampus of adolescent rats perinatally exposed to Delta(9)-THC. Pharmacol Res (2009) 0.79
WAG/Rij rats show a reduced expression of CB₁ receptors in thalamic nuclei and respond to the CB₁ receptor agonist, R(+)WIN55,212-2, with a reduced incidence of spike-wave discharges. Epilepsia (2010) 0.79
Modulatory activity of soluble beta amyloid on HPA axis function in rats. Curr Pharm Des (2014) 0.79
Cannabinoid CB1 and cholecystokinin CCK2 receptors modulate, in an opposing way, electrically evoked [3H]GABA efflux from rat cerebral cortex cell cultures: possible relevance for cortical GABA transmission and anxiety. J Pharmacol Exp Ther (2009) 0.79
5-S-cysteinyldopamine neurotoxicity: Influence on the expression of α-synuclein and ERp57 in cellular and animal models of Parkinson's disease. J Neurosci Res (2013) 0.79